免疫检查点或BRAF/MEK抑制剂治疗与晚期皮肤黑色素瘤患者葡萄膜炎的关联
共304例(64%)接受免疫检查点治疗,186例(38%)接受BRAF/MEK抑制剂治疗,中位随访74天。普通人群年葡萄膜炎发生概率估计为0.05%(95%CrI 0.02%-0.1%),治疗相关葡萄膜炎后验概率分别为免疫检查点3.48%(95%CrI 0.93%-7.49%)和BRAF/MEK抑制剂5.04%(95%CrI 2.07%-9.19%),差异后验概率76%。结论认为两类治疗均与葡萄膜炎风险增加相关,尤其BRAF/MEK抑制剂,且治疗相关葡萄膜炎与全身不良事件无关。
要点
- 免疫检查点或BRAF/MEK抑制剂治疗与晚期皮肤黑色素瘤患者葡萄膜炎风险增加相关。
- BRAF/MEK抑制剂治疗相关葡萄膜炎后验概率高于免疫检查点治疗(5.04% vs 3.48%)。
- 治疗相关葡萄膜炎与免疫检查点或BRAF/MEK抑制剂的全身不良事件无关。
核心结论
- 免疫检查点和BRAF/MEK抑制剂治疗均与晚期皮肤黑色素瘤患者葡萄膜炎风险增加相关,尤其BRAF/MEK抑制剂。
- 治疗相关葡萄膜炎与免疫检查点或BRAF/MEK抑制剂的全身不良事件无关。
研究设计与样本
- 采用贝叶斯框架和右删失指数生存模型估计葡萄膜炎发生概率。
主要发现
- 共304例(64%)接受免疫检查点治疗,186例(38%)接受BRAF/MEK抑制剂治疗。
- 普通人群年葡萄膜炎发生概率估计为0.05%(95%CrI 0.02%-0.1%)。
- 免疫检查点治疗相关葡萄膜炎后验概率为3.48%(95%CrI 0.93%-7.49%)。
- BRAF/MEK抑制剂治疗相关葡萄膜炎后验概率为5.04%(95%CrI 2.07%-9.19%),差异后验概率76%。
临床怎么用
- 对接受免疫检查点或BRAF/MEK抑制剂治疗的晚期皮肤黑色素瘤患者,应警惕葡萄膜炎这一罕见但可能导致法定失明的眼部不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with immune checkpoint and BRAF/MEK inhibitors has significantly improved the survival of patients with advanced cutaneous melanoma and other metastatic malignancies. Therapy-related uveitis is a rare ocular adverse event, which may potentially lead to legal blindness. The epidemiology of treatment-related uveitis is currently insufficiently known. PATIENTS AND METHODS: In this cohort study, we asked whether exposure to either immune checkpoint or BRAF/MEK inhibitors was associated with a higher risk of developing uveitis compared with the general population. Based on a Bayesian framework, we estimated the probability of developing uveitis with a right-censored, exponential survival model using data from the Zurich Melanoma Registry. The registry included all adult patients treated for advanced cutaneous melanoma between January 2008 and December 2018 at the University Hospital of Zurich, Switzerland. RESULTS: In total, 304 patients (64%) were treated with immune checkpoint and 186 patients (38%) with BRAF/MEK inhibitors. Median follow-up time was 74 days (interquartile range: 57-233 days). Eleven patients developed uveitis and 30 patients died. We estimated the probability of developing uveitis per year in the general population as 0.05% (95% credibility interval [CrI]: 0.02%-0.1%). Corresponding posterior probabilities of treatment-related uveitis were 3.48% (95% CrI: 0.93%-7.49%) and 5.04% (95% CrI: 2.07%-9.19%) for immune checkpoint or BRAF/MEK inhibitors (posterior probability for difference: 76%). CONCLUSIONS: Immune checkpoint and particularly BRAF/MEK inhibitor therapies are associated with an increase in the risk of developing uveitis. Treatment-related uveitis is not associated with systemic adverse events of immune checkpoint or BRAF/MEK inhibitors.
引用
- Dimitriou F, Urner-Bloch U, Eggenschwiler C, et al. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Eur J Cancer. 2020. PMID: 33373866. doi:10.1016/j.ejca.2020.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。